Loop Diuretics in the Treatment of Hypertension
详细信息    查看全文
  • 作者：Line Malha ; Samuel J. Mann
  • 关键词：Hypertension ; Diuretics ; Loop diuretics ; Torsemide ; Furosemide
  • 刊名：Current Hypertension Reports
  • 出版年：2016
  • 出版时间：April 2016
  • 年：2016
  • 卷：18
  • 期：4
  • 全文大小：357 KB
  • 参考文献：1.Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–52. doi:10.​1161/​01.​HYP.​0000107251.​49515.​c2 .CrossRef PubMed
    2.•
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20. doi:10.​1001/​jama.​2013.​284427 . Current North American guidelines for the treatment of hypertension.CrossRef PubMed
3.•
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219. doi:10.​1093/​eurheartj/​eht15110.​1093/​eurheartj/​eht151 . Current European guidelines for the treatment of hypertension.CrossRef PubMed
4.Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105–87. doi:10.​1097/​HJH.​0b013e3281fc975a​ .CrossRef PubMed
5.Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Expert Opin Pharmacother. 2014;15(5):605–21. doi:10.​1517/​14656566.​2014.​879117 .CrossRef PubMed
6.Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J Med. 2009;361(22):2153–64. doi:10.​1056/​NEJMra0907219 .CrossRef PubMed
7.Tu W, Pratt JH. A consideration of genetic mechanisms behind the development of hypertension in blacks. Curr Hypertens Rep. 2013;15(2):108–13. doi:10.​1007/​s11906-013-0332-9 .CrossRef PubMed PubMedCentral
8.Chun TY, Bankir L, Eckert GJ, Bichet DG, Saha C, Zaidi SA, et al. Ethnic differences in renal responses to furosemide. Hypertension. 2008;52(2):241–8. doi:10.​1161/​hypertensionaha.​108.​109801 .CrossRef PubMed
9.Davidov M, Kakaviatos N, Finnerty Jr FA. Antihypertensive properties of furosemide. Circulation. 1967;36(1):125–35.CrossRef PubMed
10.Healy JJ, McKenna TJ, Canning BS, Brien TG, Duffy GJ, Muldowney FP. Body composition changes in hypertensive subjects on long-term oral diuretic therapy. Br Med J. 1970;1(5698):716–9.CrossRef PubMed PubMedCentral
11.Orlov SN, Tremblay J, Hamet P. NKCC1 and hypertension: a novel therapeutic target involved in the regulation of vascular tone and renal function. Curr Opin Nephrol Hypertens. 2010;19(2):163–8. doi:10.​1097/​MNH.​0b013e3283360a46​ .CrossRef PubMed
12.Fortuno A, Muniz P, Ravassa S, Rodriguez JA, Fortuno MA, Zalba G, et al. Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension. 1999;34(1):138–43.CrossRef PubMed
13.Hocherl K, Kees F, Kramer BK, Kurtz A. Cyclosporine A attenuates the natriuretic action of loop diuretics by inhibition of renal COX-2 expression. Kidney Int. 2004;65(6):2071–80. doi:10.​1111/​j.​1523-1755.​2004.​00627.​x .CrossRef PubMed
14.Harris RC, Zhang MZ, Cheng HF. Cyclooxygenase-2 and the renal renin-angiotensin system. Acta Physiol Scand. 2004;181(4):543–7. doi:10.​1111/​j.​1365-201X.​2004.​01329.​x .CrossRef PubMed
15.Matzdorf C, Kurtz A, Hocherl K. COX-2 activity determines the level of renin expression but is dispensable for acute upregulation of renin expression in rat kidneys. Am J Physiol Ren Physiol. 2007;292(6):F1782–90. doi:10.​1152/​ajprenal.​00513.​2006 .CrossRef
16.•
Musini VM, Rezapour P, Wright JM, Bassett K, Jauca CD. Blood pressure-lowering efficacy of loop diuretics for primary hypertension. Cochrane Database Syst Rev. 2015;5, CD003825. doi:10.​1002/​14651858.​CD003825.​pub4 . Interesting review of antihypertensive effects of loop diuretics.PubMed
17.Wertheimer L, Finnerty Jr FA, Bercu BA, Hall RH. Furosemide in essential hypertension. A statistical analysis of three double-blind studies. Arch Intern Med. 1971;127(5):934–8.CrossRef PubMed
18.Achhammer I, Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs. 1991;41 Suppl 3:80–91.CrossRef PubMed
19.Spannbrucker N, Achhammer I, Metz P, Glocke M. Comparative study on the antihypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Arzneimittelforschung. 1988;38(1A):190–3.PubMed
20.Dupont AG, Schoors D, Six RO, Vanhaelst L. Antihypertensive efficacy of low dose torasemide in essential hypertension: a placebo-controlled study. J Hum Hypertens. 1988;2(4):265–8.PubMed
21.Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther. 1993;7 Suppl 1:63–8.CrossRef PubMed
22.Brater DC. Clinical pharmacology of loop diuretics. Drugs. 1991;41 Suppl 3:14–22.CrossRef PubMed
23.Vasavada N, Saha C, Agarwal R. A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. Kidney Int. 2003;64(2):632–40. doi:10.​1046/​j.​1523-1755.​2003.​00124.​x .CrossRef PubMed
24.Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol. 1995;26(3):394–400.CrossRef PubMed
25.Agarwal R, Sinha AD, Pappas MK, Ammous F. Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Am J Nephrol. 2014;39(2):171–82. doi:10.​1159/​000358603 .CrossRef PubMed
26.Broekhuysen J, Deger F, Douchamps J, Ducarne H, Herchuelz A. Torasemide, a new potent diuretic. Double-blind comparison with furosemide. Eur J Clin Pharmacol. 1986;31(Suppl):29–34.CrossRef PubMed
27.Dunn CJ, Fitton A, Brogden RN. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs. 1995;49:121–42.CrossRef PubMed
28.Knauf H, Mutschler E. Clinical pharmacokinetics and pharmacodynamics of torasemide. Clin Pharmacokinet. 1998;34(1):1–24. doi:10.​2165/​00003088-199834010-00001 .CrossRef PubMed
29.Luft FC. Torasemide in the treatment of arterial hypertension. J Cardiovasc Pharmacol. 1993;22 Suppl 3:S32–9.CrossRef PubMed
30.Vlase H. Effectiveness of furosemide in uncontrolled hypertension in the elderly: role of renin profiling. Am J Hypertens. 2003;16(3):187–93. doi:10.​1016/​s0895-7061(02)03260-0 .CrossRef PubMed
31.Vadasz TA, Chadha DR. Experience with once-daily and twice-daily slow-release frusemide in hypertension. J Int Med Res. 1982;10(4):199–203.PubMed
32.Araoye MA, Chang MY, Khatri IM, Freis ED. Furosemide compared with hydrochlorothiazide. Long-term treatment of hypertension. JAMA. 1978;240(17):1863–6.CrossRef PubMed
33.Finnerty Jr FA, Maxwell MH, Lunn J, Moser M. Long-term effects of furosemide and hydrochlorothiazide in patients with essential hypertension a two-year comparison of efficacy and safety. Angiology. 1977;28(2):125–33.CrossRef PubMed
34.Valmin K, Hansen T. Treatment of benign essential hypertension: comparison of furosemide and hydrochlorothiazide. Eur J Clin Pharmacol. 1975;8(6):393–401.CrossRef PubMed
35.Ram CV, Garrett BN, Kaplan NM. Moderate sodium restriction and various diuretics in the treatment of hypertension. Arch Intern Med. 1981;141(8):1015–9.CrossRef PubMed
36.Anderson J, Godfrey BE, Hill DM, Munro-Faure AD, Sheldon J. A comparison of the effects of hydrochlorothiazide and of frusemide in the treatment of hypertensive patients. Q J Med. 1971;40:541–60.PubMed
37.Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002;39(5):982–8.CrossRef PubMed
38.Vaughan Jr ED, Laragh JH, Gavras I, Bühler FR, Gavras H, Brunner HR, et al. Volume factor in low and normal renin essential hypertension: treatment with either spironolactone or chlorthalidone. Am J Cardiol. 1973;32(4):523–32. doi:10.​1016/​S0002-9149(73)80044-X .CrossRef PubMed
39.•
Mann SJ, Ernst ME. Personalizing the diuretic treatment of hypertension: the need for more clinical and research attention. Curr Hypertens Rep. 2015;17(4):542. doi:10.​1007/​s11906-015-0542-4 . Review of subtleties of diuretic use in hypertension.CrossRef PubMed
40.Egan BM, Basile JN, Rehman SU, Davis PB, Grob 3rd CH, Riehle JF, et al. Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens. 2009;22(7):792–801. doi:10.​1038/​ajh.​2009.​63 .CrossRef PubMed
41.Wilcox CS, Mitch WE, Kelly RA, Skorecki K, Meyer TW, Friedman PA, et al. Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. J Lab Clin Med. 1983;102:450–8.PubMed
42.Ellison DH. Diuretic resistance: physiology and therapeutics. Semin Nephrol. 1999;19(6):581–97.PubMed
43.Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. Arch Intern Med. 1991;151:1786–92.CrossRef PubMed
44.Shen W, Khwaja F, Feig PU, Shah S, Wilcox C. A novel extended release formulation of torsemide enhances natriuresis without lowering Gfr in normal human subjects. J Am Coll Cardiol. 2014;63(12_S). doi: 10.​1016/​S0735-1097(14)61401-7
45.Lambe R, Kennedy O, Kenny M, Darragh A. Study of the tolerance and diuretic properties of torasemide following oral or intravenous administration to healthy volunteers. Eur J Clin Pharmacol. 1986;31(Suppl):9–14.CrossRef PubMed
46.Reyes AJ, Leary WP. Renal excretory responses to single and repeated administration of diuretics in healthy subjects: clinical connotations. Cardiovasc Drugs Ther. 1993;7 Suppl 1:29–44.CrossRef PubMed
47.Uchida T, Yamanaga K, Nishikawa M, Ohtaki Y, Kido H, Watanabe M. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol. 1991;205(2):145–50.CrossRef PubMed
48.McAdams DeMarco MA, Maynard JW, Baer AN, Gelber AC, Young JH, Alonso A, et al. Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study. Arthritis Rheum. 2012;64(1):121–9. doi:10.​1002/​art.​33315 .CrossRef PubMed PubMedCentral
49.Holland OB, Pool PE. Metabolic changes with antihypertensive therapy of the salt-sensitive patient. Am J Cardiol. 1988;61(16):53H–9H.CrossRef PubMed
50.Jackson WP, Nellen M. Effect of frusemide on carbohydrate metabolism, blood-pressure, and other modalities. A comparison with chlorothiazide. Br Med J. 1966;2(5509):333–6.CrossRef PubMed PubMedCentral
51.Mann SJ. The silent epidemic of thiazide-induced hyponatremia. J Clin Hypertens (Greenwich). 2008;10(6):477–84.CrossRef
52.Spital A. Diuretic-induced hyponatremia. Am J Nephrol. 1999;19(4):447–52. doi:13496.CrossRef PubMed
53.Kazory A. Hyponatremia in heart failure: revisiting pathophysiology and therapeutic strategies. Clin Cardiol. 2010;33(6):322–9. doi:10.​1002/​clc.​20791 .CrossRef PubMed
54.Porzio P, Halberthal M, Bohn D, Halperin ML. Treatment of acute hyponatremia: ensuring the excretion of a predictable amount of electrolyte-free water. Crit Care Med. 2000;28(6):1905–10.CrossRef PubMed
55.Sunderam SG, Mankikar GD. Hyponatraemia in the elderly. Age Ageing. 1983;12(1):77–80.CrossRef PubMed
56.Sonnenblick M, Friedlander Y, Rosin AJ. Diuretic-induced severe hyponatremia. Review and analysis of 129 reported patients. Chest. 1993;103(2):601–6.CrossRef PubMed
57.Byatt CM, Millard PH, Levin GE. Diuretics and electrolyte disturbances in 1000 consecutive geriatric admissions. J R Soc Med. 1990;83(11):704–8.PubMed PubMedCentral
58.Wright Jr JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16. doi:10.​1056/​NEJMoa1511939 .CrossRef PubMed
59.Garrison SR, Dormuth CR, Morrow RL, Carney GA, Khan KM. Nocturnal leg cramps and prescription use that precedes them: a sequence symmetry analysis. Arch Intern Med. 2012;172(2):120–6. doi:10.​1001/​archinternmed.​2011.​1029 .CrossRef PubMed
60.Ikeda K, Oshima T, Hidaka H, Takasaka T. Molecular and clinical implications of loop diuretic ototoxicity. Hear Res. 1997;107(1–2):1–8.CrossRef PubMed
61.Salvador DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev. 2004;1, CD003178. doi:10.​1002/​14651858.​CD003178.​pub2 .PubMed
62.Gallagher KL, Jones JK. Furosemide-induced ototoxicity. Ann Intern Med. 1979;91(5):744–5.CrossRef PubMed
63.Brown CB, Ogg CS, Cameron JS. High dose frusemide in acute renal failure: a controlled trial. Clin Nephrol. 1981;15(2):90–6.PubMed
64.Wulf NR, Matuszewski KA. Sulfonamide cross-reactivity: is there evidence to support broad cross-allergenicity? Am J Health Syst Pharm. 2013;70(17):1483–94. doi:10.​2146/​ajhp120291 .CrossRef PubMed
65.Strom BL, Schinnar R, Apter AJ, Margolis DJ, Lautenbach E, Hennessy S, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 2003;349(17):1628–35. doi:10.​1056/​NEJMoa022963 .CrossRef PubMed
66.Loon NR, Wilcox CS, Unwin RJ. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int. 1989;36(4):682–9.CrossRef PubMed
67.•Dussol B, Moussi-Frances J, Morange S, Somma-Delpero C, Mundler O, Berland Y. A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. J Clin Hypertens (Greenwich). 2012;14(1):32–7. doi:10.​1111/​j.​1751-7176.​2011.​00564.​x . Interesting article challenging the common misconception that thiazide diuretics have no effect in patients with kidney disease.CrossRef
68.Wollam GL, Tarazi RC, Bravo EL, Dustan HP. Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. Am J Med. 1982;72(6):929–38.CrossRef PubMed
69.Setaro JF, Black HR. Refractory hypertension. N Engl J Med. 1992;327(8):543–7. doi:10.​1056/​nejm199208203270​808 .CrossRef PubMed
70.Ellison DH. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med. 1991;114(10):886–94.CrossRef PubMed
71.Laragh JH, Sealey JE. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. Am J Hypertens. 2011;24(11):1164–80. doi:10.​1038/​ajh.​2011.​171 .CrossRef PubMed
72.Cody RJ, Laragh JH, Case DB, Atlas SA. Renin system activity as a determinant of response to treatment in hypertension and heart failure. Hypertension. 1983;5(5 Pt 2):III36–42.PubMed
73.Ramsay LE, Silas JH, Freestone S. Diuretic treatment of resistant hypertension. Br Med J. 1980;281(6248):1101–3.CrossRef PubMed PubMedCentral
74.Verdalles U, de Vinuesa SG, Goicoechea M, Quiroga B, Reque J, Panizo N, et al. Utility of bioimpedance spectroscopy (BIS) in the management of refractory hypertension in patients with chronic kidney disease (CKD). Nephrol Dial Transplant. 2012;27 Suppl 4:iv31–5. doi:10.​1093/​ndt/​gfs420 .CrossRef PubMed
75.Molnar J, Somberg JC. The clinical pharmacology of ethacrynic acid. Am J Ther. 2009;16(1):86–92. doi:10.​1097/​MJT.​0b013e318195e460​ .CrossRef PubMed
76.Porcellati C, Verdecchia P, Schillaci G, Guerrieri M, Boldrini F, Gatteschi C, et al. Torasemide treatment of arterial hypertension. Basi Razionali della Terapia. 1990;20(5):407–10.
77.Reyes AJ, Chiesa PD, Santucci MR, Batista LB, Olhaberry JV, Mosler AL, et al. Hydrochlorothiazide versus a non-diuretic dose of torasemide as once-daily antihypertensive monopharmacotherapy in elderly patients. A randomized and double-blind study. Prog Pharmacol Clin Pharmacol. 1990;8(1):183–209.
78.Boelke T, Achhammer I, Meyer-Sabellek WA. Blutdrucksenkung und metabolische Veranderungen bei essentiellen Hypertonikern nach Langzeitgabe unterschiedlicher Diuretika. Hochdruck. 1990;9:40–1.
79.Boelke T, Achhammer I, Meyer-Sabellek WA, et al. Tagesund Nachrthythmik ambulanter 24-h Blutdruckwerte von alteren essentiellen Hypertonikern bei Therapie mit verschiedenen Antihypertonika. Hochdruck. 1990;10.
  • 作者单位：Line Malha (1)
    Samuel J. Mann (1)

    1. Department of Nephrology and Hypertension, Hypertension Center, NY Presbyterian Hospital–Weill Cornell Medicine, 424 E. 70th Street, New York, NY, 10021, USA
  • 刊物主题：Internal Medicine; Cardiology; Metabolic Diseases; Nephrology; Primary Care Medicine; General Practice / Family Medicine;
  • 出版者：Springer US
  • ISSN：1534-3111
    • 文摘
    Loop diuretics are not recommended in current hypertension guidelines largely due to the lack of outcome data. Nevertheless, they have been shown to lower blood pressure and to offer potential advantages over thiazide-type diuretics. Torsemide offers advantages of longer duration of action and once daily dosing (vs. furosemide and bumetanide) and more reliable bioavailability (vs. furosemide). Studies show that the previously employed high doses of thiazide-type diuretics lower BP more than furosemide. Loop diuretics appear to have a preferable side effect profile (less hyponatremia, hypokalemia, and possibly less glucose intolerance). Studies comparing efficacy and side effect profiles of loop diuretics with the lower, currently widely prescribed, thiazide doses are needed. Research is needed to fill gaps in knowledge and common misconceptions about loop diuretic use in hypertension and to determine their rightful place in the antihypertensive arsenal.

    © 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

    地址：北京市海淀区学院路29号 邮编：100083

    电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700